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Available online 28 April 2015Posterior reversible leukoencephalopathy syndrome
(PRES) is a rare and severe complication of calcineurin inhi-
bitor neurotoxicity, especially following high risk proce-
dures, such as hematopoietic stem cell transplantation
(HSCT). We report an isolated brainstem localization of
PRES in a 23-year-old patient who, two days following
cyclosporine (CsA) administration, manifested gradual
symptoms that included hypertension, vomiting, vertigo,
tremor, nystagmus, and visual disturbance. Radiologic mag-
netic resonance imaging (MRI) showed two bilateral puncti-
form, increased signals on T2 with fluid attenuation
inversion recovery (FLAIR) in the pons. The patient’s symp-
toms, as well as MRI signs, were resolved when the cyclos-
porine treatment was discontinued.
Posterior reversible leukoencephalopathy syndrome
(PRES) is a rare clinical and radiological inflammatory com-
plication, involving the central nervous system and the
impairment of the blood brain barrier. Clinical symptoms
may include headache, vomiting, mental confusion, sei-
zures, coma, cortical blindness and other neurological dis-
orders [1]. These symptoms have been reported inpatients with severe hypertension, eclampsia, hemolytic
uremic syndrome, and are also associated with neurotoxic
drugs such as cyclosporine (CsA) and tacrolimus. Radiologic
magnetic resonance imaging (MRI) is the gold standard diag-
nostic test for the posterior regions of the parietal, tempo-
ral and occipital lobes, which are the classic locations for
PRES [2].
We report an atypical case of PRES with isolated brain-
stem localization, related to CsA, in a 23-year-old male
patient who had a sibling-matched bone marrow transplant
for severe aplastic anemia. The conditioning regimen con-
sisted of cyclophosphamide (200 mg/kg, i.v.) and rabbit
anti-thymocyte globulin (rATG) (12 mg/kg, i.v.). To prevent
cytokine release syndrome related to rATG, antihistaminic
and methyl prednisone (2 mg/kg/day, i.v.) was adminis-
tered over five days. Prophylaxis of graft versus host disease
(GVHD) consisted of post-graft CsA (Sandimmun) adminis-
tered at a dose of 3 mg/kg/day by continuous infusion
started at day 1 before graft, with a maintained therapeutic
range between 200–400 ng/ml, and methotrexate.
Acyclovir was also prescribed to prevent Herpes simplex
virus (HSV).
On day 1 post transplant (two days after CsA administra-
tion), the patient experienced an inexplicably high level of
igure 1 Retinal angiography on diagnosis. Right eye.
Figure 2a MRI showing two bilateral punctiform (arrows)
increased signal on T2 together with fluid attenuation inversion
recovery (FLAIR) in the pons.
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physical examination there were cutaneous and mucous
paleness, regular respiratory rhythm with an oxygen satura-
tion of 99% while inhaling ambient air. Cardiac auscultation
revealed regular tachycardia (100 beats per minute) without
extraneous sounds. Neurological examination showed nor-
mal strength sensation as well as normal gait and coordina-
tion. Peripheral blood count showed neutropenia (100/ll),
anemia (9.6 g/dl), and thrombocytopenia (77,000/ll).
Serum creatinine level, serum sodium concentration, AST,
and ALT were normal. Serum cholesterol was low at
0.93 g/l and serum CsA was within therapeutic range
(218 ng/ml). Other laboratory tests were normal. Mean
arterial blood was maintained below 100 mmHg through
continual infusion of nicardipine.
Twenty days later, the patient developed vomiting, ver-
tigo, and visual disturbance. Physical examination showed
bilaterally decreased vision, asymmetry of the pupils, nys-
tagmus, tremor, and imbalance in resting state. The patient
was apyretic, with normal blood pressure (110/70 mmHg).
The fundus examination, fluorescence angiography and
visual field tests found papilledemawith retinal hemorrhages
and visual disturbances; and a diagnosis of bilateral edema-
tous optic neuropathy was made (Fig. 1). MRI showed two
bilateral punctiform and increased signals on T2, together
with fluid attenuation inversion recovery (FLAIR) in the pons
(Fig. 2a), which confirmed diagnosis of isolated brainstem
localization of an atypical PRES. Residual CsA was in the
upper limit of the therapeutic range (384 ng/ml). We discon-
tinued cyclosporine, replacing it on the same day with tacro-
limus (Prograf). An additional continuous infusion of
magnesium (4 mg/24Hr. i.v.) was administered. Blood cryp-
tococcus antigen by enzyme immunoassay test was negative.
Forty-eight hours later, the patient’s vertigo and ability to
see color started to improve. Complete resolution of neuro-
logic signs was achieved two weeks after the onset of the
symptoms with disappearance of the brainstem lesions in
brain MRI control (Fig. 2b). The fluorescence angiography
and the visual field tests revealed a remarkable decrease of
inflammatory optic signs and improvement of visual acuity.
Engraftment was achieved successfully at day 33. With a fol-
low up of 15 months, patient is alive with no further
complications.
Bone marrow transplant offers a curative treatment for
young patients with acquired severe aplastic anemia when
human leukocyte antigen (HLA) identical sibling donor is
available. Calcineurin inhibitors such as CsA are considered
the standard GVHD prophylaxes. However, among their side
effects, neurological toxicity can cause serious complica-
tions such as PRES. Siegal et al. recently reported an inci-
dence rate of 7% among 302 consecutive recipients who
underwent HSCT for malignant and non-malignant hemato-
logic diseases, with a significant inferior survival rate at
one year in PRES versus no PRES groups (27% vs 63%, respec-
tively) [3].
Vasogenic edema, which predominantly affects the
white matter of cerebral hemispheres, especially posterior
regions, occurs due to the differences in sympathetic inner-
vations between the anterior and posterior circulation. The
posterior region of the brain is the classic location of PRES
because it is more vulnerable to the excessive perfusion
pressure that is associated with systemic hypertension [4].FIn our case, MRI showed that the brainstem was predomi-
nantly involved, whereas the occipital lobes were spared.
Mechanisms of brainstem involvement have been postulated
byDoi et al. Extensive fluid leakage in the brainstemmay spare
the parietal and occipital regions in the distal portion of the
vertebra-basilar artery system, or relatively rich sympathetic
nerve innervations may occur in the parieto-occipital region,
which is mainly supplied via the posterior communicating
artery from the anterior circulation [5].
CsA is known to be highly lipophilic, with about 80%
plasma binding to high and low-density lipoprotein. In con-
trast, a low rate of serum cholesterol can result in increased
unbound CsA, which may cause neurotoxicity, fluid
retention, and which has a direct toxic effect on the vascu-
lar endothelium, resulting in the release of endothelin
Figure 2b MRI on day 16 showing improvement.
38 N. Yafour et al.prostacyclin and thromboxane A2 and, consequently,
apoptosis on brain capillary endothelial cells.
Our patient was at high risk for the development of neuro-
toxicity for two reasons: first, he had a low rate of choles-
terol; and second, a high-dose of methyl prednisone used to
prevent cytokine release syndrome may have potentiated
the neurotoxic effect of CsA [6]. Other risk factors described
in the literature include low magnesium, aluminum over-
loads, or the association of CsA with voriconazole.
The distribution of lesions in bilaterally symmetric
brainstem is an uncommon localization of PRES. In this case,we suspected secondary to CsA neurotoxicity because of the
rapid improvement after the discontinuation of cyclosporine.
Conclusion
PRES is typically reversible but unless recognized early
and treated appropriately permanent brain injury may
ensue. It is very important to identify and prevent this
complication in high-risk HSCT patients; we also support
the recommendation of an appropriate prophylaxis for
PRES.
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